Strengthening Our Leadership in Patient-Specific Insulin Dosing

Q3 CEO Quarterly Update

As we wrap up the third quarter of 2024, it’s a great opportunity to reflect on the remarkable progress Monarch Medical Technologies has made so far this year. From the significant strides in solidifying our leadership in patient-specific insulin dosing, to the ongoing advancements in our EndoTool platform and successful rebranding.

Innovation has always been at the core of Monarch’s mission. Over the years, we have consistently enhanced our EndoTool platform to better serve healthcare providers and their patients.

A key example is the Estimated Residual Extracellular Insulin (EREI) feature, which continues to set the standard for patient safety by preventing insulin stacking and reducing the risk of hypoglycemia. These innovations are not just technical achievements—they directly translate into improved outcomes for our customers.

In fact, customer outcomes from last year demonstrate that EndoTool virtually eliminates severe hypoglycemia, a critical factor in improving patient safety and overall care quality. These results are a testament to the impact EndoTool is having in clinical settings. This kind of ongoing innovation, paired with a focus on improving workflow and usability, is what keeps EndoTool at the forefront of glycemic management.

Commitment to Quality and Safety

Our commitment to quality and safety remains unwavering. In an industry where trust is paramount, we take pride in ensuring that EndoTool is not only the most advanced glucose management system available but also one of the most reliable.

We’ve worked diligently to uphold the highest standards, which is why so many leading healthcare systems across the country continue to choose Monarch as their trusted partner in patient care.

Celebrating Recent Successes

One of our most significant accomplishments this quarter has been the public launch of our new brand identity. This rebranding was more than just a visual makeover; it was a strategic effort to position Monarch as the undisputed leader in patient-specific insulin dosing. The positive feedback from our customers, partners, and the broader healthcare community has been incredibly encouraging.

We’re especially proud that 8 out of the top 10 healthcare systems in the country now trust EndoTool to manage their patients’ glycemic control—an endorsement of the confidence the industry places in our solutions.

Looking Ahead

As we head into the last quarter of 2024, our focus will be on sustaining the momentum we’ve built so far. We will continue to innovate, expand and most importantly, support our customers in delivering the highest standard of care. The future of glycemic management is bright, and Monarch Medical Technologies is poised to lead the way.

I want to thank every member of the Monarch team for their hard work and dedication. It is through your efforts that we can make a meaningful impact on patient care. Together, we are creating a world where every inpatient insulin dose is the right one.

Thank you for your continued support, and here’s to a strong finish to 2024!